Infect Chemother.  2019 Jun;51(2):183-187. 10.3947/ic.2019.51.2.183.

Seroprevalence of Hepatitis A Virus in Pediatric Patients with Hematologic Malignancies after Chemotherapy and Hematopoietic Cell Transplantation

Affiliations
  • 1Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. beomsid@catholic.ac.kr
  • 2Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 3The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Abstract

This retrospective study was performed to determine the seroprevalence of hepatitis A virus (HAV) in children and adolescents with hematologic malignancies after the completion of chemotherapy and hematopoietic cell transplantation (HCT). Of 97 enrolled patients, 60 (61.9%) were seropositive for HAV. The seroprevalences in patients undergoing chemotherapy and HCT were 60.3% (41/68) and 65.5% (19/29), respectively (P = 0.628). No significant factors associated with seropositivity for HAV after chemotherapy and HCT were identified. Anti-HAV tests and HAV re-vaccinations can be considered in children and adolescents with underlying hematologic malignancies after chemotherapy and HCT based on the anti-HAV results.

Keyword

Chemotherapy; Stem cell transplantation; Hepatitis A virus; Seroprevalence; Child

MeSH Terms

Adolescent
Cell Transplantation*
Child
Drug Therapy*
Hematologic Neoplasms*
Hepatitis A Antibodies
Hepatitis A virus*
Hepatitis A*
Hepatitis*
Humans
Retrospective Studies
Seroepidemiologic Studies*
Stem Cell Transplantation
Transplants*
Hepatitis A Antibodies
Full Text Links
  • IC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error